Led by University of Michigan researcher Dr. Anna Lok, this study indicates that interferon free treatment for hepatitis C may be possible in the near future.
“In this pilot study, patients with hepatitis C genotype 1 infection, who had not responded to previous treatment with PEG-interferon alfa and ribavirin, were given a combination of two investigational direct-acting antiviral agents (daclatasvir and asunaprevir) alone, or were given these two antiviral agents along with PEG-interferon alfa-2a and ribavirin.”
“Although only four of 11 patients given the two direct-acting antiviral agents only achieved sustained virologic response, this is the first study to show that sustained virologic response can be achieved without the use of interferon or ribavirin.”
Dr. Lok’s research is funded in part by the Ann Arbor-based Greenview Foundation Hepatitis C Research Fund.
For the full article please go to: